SEE FULL COMPANY PROFILES WITH A FREE TRIAL
EMIS is the definitive emerging markets news, research, company, and financial data resource. EMIS - ISI Emerging MarketsLEARN MORE
Search for another company:
ALL
Chile
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).

Laboratorios Andromaco S.A.

Main Activities: Pharmaceutical and Medicine Manufacturing

facebook Please check the full coverage of information what EMIS can offer you. SEE SAMPLE

Company Information

Full name
Laboratorios Andromaco S.A.

Headquarters
Blvd. Quilin 5273 Peñalolen; Santiago; Metropolitana
Status: Listed
Legal Form: Public Limited Company
Operational Status: Operational
Fiscal ID (RUT): 924480009
Fiscal ID (ISIN CODE ): CL0000000464
Financial Auditors: Ernst & Young (2011)
Incorporation Date: August 30, 2000
Total Employees: 761

Tel: +56 2 594 8000

Company Description

Marketing and production of drugs of excellent quality and efficiency. The company represents important international pharmaceuticals firms, through which it incorporates exclusive and innovative products to its offer, for disease prevention and treatment. In addition, Andrómaco plays an active role contributing to generate pharmaceutical knowledge trough the research and development of vanguard products. The company is formed by Laboratorios Andrómaco S.A., Laboratorios Silesia S.A., ABL Pharma,
More

Key Executives

Sergio Weinstein Aranda President of the Board Directors
Andrés Rudolphy Fontaine Vice President of the Board Directors
José Ignacio Iñíguez Díaz Marketing Manager
Juan Carlos Gómez Vargas Sales Manager
Carlos Cruz León Operations Manager
More
SEE FULL COMPANY PROFILES WITH A FREE TRIAL
EMIS is the definitive emerging markets news, research, company, and financial data resource. EMIS - ISI Emerging MarketsLEARN MORE
ISI Emerging Markets

FULL COMPANY PROFILE

Please check the full coverage of information what EMIS can offer you.
SEE SAMPLE
SELECT CURRENCY
2013 Y
(cons)
2013 Q3C
(cons)
Audited Audited
Unit Thousands Thousands
Balance Sheet

Total Assets

XXX

XXX

Current Assets

XXX

XXX

Total Liabilities

XXX

XXX

Shareholders Equity

XXX

XXX

Current Liabilities

XXX

XXX

* All the accounts are in CLP.
Income Statement

Total Operating Revenue

XXX

XXX

Operational Profit (Loss)

XXX

XXX

Net Profit (Loss)

XXX

XXX

* All the accounts are in CLP.
Ratios
Profitability Ratios

Return on Assets (ROA)

XXX

XXX

Annualised Return on Assets (ROA)

XXX

XXX

Return on Equity (ROE)

XXX

XXX

Annualised Return on Equity (ROE)

XXX

XXX

Return on Sales (ROS)

XXX

XXX

Return on Capital

XXX

XXX

Gross Profit Margin

XXX

XXX

Operating Profit Margin

XXX

XXX

Efficiency Ratios

Accounts Receivable Turnover

XXX

XXX

Inventory Turnover

XXX

XXX

Current asset turnover

XXX

XXX

Fixed-asset turnover

XXX

XXX

Asset Turnover

XXX

XXX

Valuation figures and ratios

Earning Before Interests and Taxes (EBIT)

XXX

XXX

EBITDA

XXX

XXX

Enterprise Value / EBITDA

XXX

XXX

Bookvalue (BV)

XXX

XXX

Net Cash

XXX

XXX

Liquidity Ratios

Current Ratio

XXX

XXX

Quick ratio

XXX

XXX

Doom's day ratio

XXX

XXX

Leverage Ratios

Leverage ratio

XXX

XXX

Debt to equity

XXX

XXX

Debt to total assets

XXX

XXX

Market ratios

Market Capitalization/EBITDA

XXX

XXX

Price/Book Ratio

XXX

XXX

Market Cap / Net cash

XXX

XXX

Trend Ratios

Revenue Trend

XXX

XXX

Net Income Trend

XXX

XXX

Operating Income Trend

XXX

XXX